November 19, 2022 – Therapy with DNA repair inhibitors in early phase clinical trials

CD103 positive dendritic cell (CD103DC) counts were increased significantly between 4 and 12 weeks in Kras mice, while IL-17:Kras tumors showed significantly fewer CD103+DCs at

Day: November 19, 2022

CD103 positive dendritic cell (CD103DC) counts were increased significantly between 4 and 12 weeks in Kras mice, while IL-17:Kras tumors showed significantly fewer CD103+DCs at 12 weeks compared to Kras tumors (Supplementary figure 4A)

Day: November 19, 2022

﻿CD103 positive dendritic cell (CD103DC) counts were increased significantly between 4 and 12 weeks in Kras mice, while IL-17:Kras tumors showed significantly fewer CD103+DCs at 12 weeks compared to Kras tumors (Supplementary figure 4A)

CD103 positive dendritic cell (CD103DC) counts were increased significantly between 4 and 12 weeks in Kras mice, while IL-17:Kras tumors showed significantly fewer CD103+DCs at 12 weeks compared to Kras tumors (Supplementary figure 4A)